Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly FCF Margin of 6.42% for Q1 2026, up 2953.0% year-over-year from 0.21% in Q1 2025, and up 109.15% quarter-over-quarter from 70.19% in Q4 2025.
Maravai Lifesciences Holdings (MRVI) FCF Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' FCF Margin history runs 7 years deep, the most recent figure standing at 6.42% for Q1 2026.
- In Q1 2026, FCF Margin rose 2953.0% year-over-year to 6.42%; the TTM figure through Mar 2026 stood at 27.19% (down 2953.0% YoY), while the FY2025 annual figure was 38.08%, down 3995.0% from the prior year.
- FCF Margin for Q1 2026 stood at 6.42%, up from 70.19% in the prior quarter.
- The five-year high for FCF Margin was 97.7% in Q1 2023, with the low at 70.19% in Q4 2025.
- The 5-year median for FCF Margin is 6.58% (2024), against an average of 15.64%.
- The sharpest annual moves came in 2022 and 2024: FCF Margin surged 4068 bps in 2022, then slumped 11582 bps in 2024.
- Maravai Lifesciences Holdings' FCF Margin stood at 53.01% in 2022, then surged by 39 bps to 73.55% in 2023, then sank by 84 bps to 11.59% in 2024, then sank by 706 bps to 70.19% in 2025, then soared by 109 bps to 6.42% in 2026.
- Business Quant data shows MRVI's FCF Margin at 6.42% in Q1 2026, 70.19% in Q4 2025, and 19.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 7.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.04% |
| Mar 31, 2026 | 6.42% |
| Dec 31, 2025 | -70.19% |
| Sep 30, 2025 | -19.11% |
| Jun 30, 2025 | -35.74% |
| Mar 31, 2025 | -23.10% |
| Dec 31, 2024 | 11.59% |
| Sep 30, 2024 | 6.58% |
| Jun 30, 2024 | 7.75% |
| Mar 31, 2024 | -18.12% |
| Dec 31, 2023 | 73.55% |
| Sep 30, 2023 | -2.48% |
| Jun 30, 2023 | -8.51% |
| Mar 31, 2023 | 97.70% |
| Dec 31, 2022 | 53.01% |
| Sep 30, 2022 | 54.16% |
| Jun 30, 2022 | 66.58% |
| Mar 31, 2022 | 65.73% |
| Dec 31, 2021 | 28.80% |
| Sep 30, 2021 | 47.56% |